CD274 and mucosal melanoma: ARTISTRY-6, a phase II study, is evaluating the efficacy of ALKS 4230 monotherapy administered subcutaneously in patients with advanced cutaneous or mucosal melanoma who have previously received anti-PD-(L)1 therapy (NCT04830124).